Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix® with a favorable tolerability profile

Newly presented data outline robust polyfunctional CD4+ T-cell responses in Z-1018 arms

Company initiates Part 2 of Phase 1/2 head-to-head versus Shingrix in adults 70 years and older

EMERYVILLE, Calif. , Oct. 21, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today presented positive topline data from Part 1 of its randomized, observer-blinded, active-controlled Phase 1/2 clinical trial of Z-1018, the Company's novel shingles vaccine candidate, in a late-breaker session at IDWeek 2025. Dynavax also today announced it has initiated Part 2 of the trial

See Full Page